REFERENCES
- A Markham, and EM Sorkin. (1993). Ondansetron: an update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 45:931–952.
- K Takahashi, and JH Rytting. (2001). Novel approach to improve permeation of ondansetron across shed snake skin as a model membrane. J. Pharm. Pharmacol. 53:789–794.
- DA Dimas, PP Dallas, and DM Rekkas. (2004). Ion pair formation as a possible mechanism for the enhancement effect of lauric acid on the transdermal permeation of ondansetron. Pharm. Dev. Technol. 9:311–320.
- DA Dimas, PP Dallas, and DM Rekkas. (2004). Use of an 8(1)3(2) asymmetrical factorial design for the in vitro evaluation of ondansetron permeation through human epidermis. Pharm. Dev. Technol. 9:39–48.
- HS Gwak, IS Oh, and IK Chun. (2004). Transdermal delivery of ondansetron hydrochloride: effects of vehicles and penetration enhancers. Drug Dev. Ind. Pharm. 30:187–194.
- HS Gwak, IS Oh, and IK Chun. (2003). In vitro percutaneous absorption of ondansetron hydrochloride from pressure-sensitive adhesive matrices through hairless mouse skin. Arch. Pharm. Res. 26:644–648.
- YSR Krishnaiah, M Shiva Kumar, V Raju, M Lakshmi, and B Rama. (2008). Penetration enhancing effect of ethanolic solution of menthol on transdermal permeation of ondansetron hydrochloride across rat epidermis. Drug Deliv. 15:227–234.
- Y KrishnaiahSR, V Raju, Shiva Kumar, B Rama, V Raghumurthy, and KV Ramanamurthy. (2008). Studies on optimizing in vitro transdermal permeation of ondansetron hydrochloride using nerodilol, carvone and limonene as penetration enhancers. Pharm. Dev. Technol. 13:177–185.
- Y KrishnaiahSR, V Satyanarayana, and P Bhaskar. (2003). Formulation and in vivo evaluation of membrane-moderated transdermal therapeutic systems of nicardipine hydrochloride using carvone as a penetration enhancer. Drug Deliv. 10:101–109.
- PR Keshary, and YW Chien. (1984). Mechanism of transdermal controlled nitroglycerin administration. Part 2. Assessment of rate controlling steps. Drug Dev. Ind. Pharm. 10:1663–1699.
- B Barry. Transdermal drug delivery. In: ME Aulton, ed. Pharmaceutics: The Science of Dosage Form Design . 2nd ed. London: Churchill Livingstone; (2002):499–533.
- HP Bozigian, JF Pritchard, AE Gooding, and GE Pakes. (1994). Ondansetron absorption in adults: effect of dosage form, food, and antacids. J. Pharm. Sci. 83:1011–1013.
- SN Makhija, and PR Vavia. (2003). Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine. I. Cellulose acetate as a semipermeable membrane. J. Control. Release. 89:5–18.
- J Schulze Nahrup, ZM Gao, JE Mark, and A Sakr. (2004). Poly(dimethylsiloxane) coatings for controlled drug release – polymer modifications. Int. J. Pharm. 270:199–208.
- NU Rahman, and KH Yuen. (2005). Eudragit NE40-drug mixed coating system for controlling drug release of core pellets. Drug Dev. Ind. Pharm. 31:339–347.
- MC Musolf. Pressure-sensitive adhesives: science and engineering. In: YW Chien, ed. Transdermal Controlled Systemic Medications. New York: Marcel Dekker; (1987): 93–112.
- Y KrishnaiahSR, V Satyanarayana, and P Bhaskar. (2003). Influence of menthol and pressure sensitive adhesives on the in vivo performance of membrane-moderated transdermal therapeutic system of nicardipine hydrochloride in human volunteers. Eur. J. Pharm. Biopharm. 55:329–337.
- I Diez, H Colom, J Moreno, R Obach, C Peraire, and J Domenech. (1991). A comparative in vitro study of transdermal absorption of a series of calcium channel antagonists. J. Pharm. Sci. 80:931–934.
- JN Hunt, and WR Spurrell. (1951). The pattern of emptying of the human stomach. J. Physiol. 113:157–168.
- JN Hunt. (1959). Gastric emptying and secretion in man. Physiol. Rev. 39:491–533.